Tenet Healthcare shares slide 3.7% amid apparent profit-taking after recent highs

Tenet Healthcare (THC) is down 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be driven more by trading dynamics than a single fresh headline, with investors potentially taking profits after a strong run that followed upbeat full-year results and a 2026 outlook update. With the stock recently pushing to record/high levels, even modest shifts in risk appetite can translate into outsized day-to-day pullbacks.

Details:

Tenet’s most recent quarterly update highlighted strong Q4 and full-year 2025 performance and included a 2026 financial outlook, which helped set expectations and fueled prior gains.

After a sharp post-earnings rally, the stock’s positioning looked extended, which can increase sensitivity to routine selling and rebalancing.

No widely circulated, company-specific breaking item was evident alongside today’s drop, suggesting the decline may reflect profit-taking or broader healthcare/provider sector rotation (speculation).

Investors may also be recalibrating valuation and forward-growth assumptions ahead of the next earnings date on the calendar.

Sources:

Tenet Investor Relations, MarketScreener, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$THC Insider Trading Activity

$THC insiders have traded $THC stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.

Here’s a breakdown of recent trading of $THC stock by insiders over the last 6 months:

THOMAS W ARNST (EVP, Chief Admin. Officer & GC) has made 0 purchases and 3 sales selling 32,000 shares for an estimated $7,527,737.
TAMMY ROMO has made 0 purchases and 6 sales selling 27,500 shares for an estimated $5,563,324.
R. SCOTT RAMSEY (Principal Accounting Officer) has made 0 purchases and 6 sales selling 21,339 shares for an estimated $4,598,015.
PAOLA M ARBOUR (EVP, Chief Information Officer) sold 6,500 shares for an estimated $1,549,795
RICHARD W FISHER sold 2,500 shares for an estimated $521,075
NADJA WEST sold 2,178 shares for an estimated $430,089

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$THC Hedge Fund Activity

We have seen 340 institutional investors add shares of $THC stock to their portfolio, and 383 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

LONE PINE CAPITAL LLC added 1,787,326 shares (+inf%) to their portfolio in Q4 2025, for an estimated $355,177,422
WELLINGTON MANAGEMENT GROUP LLP added 1,042,260 shares (+1114.2%) to their portfolio in Q4 2025, for an estimated $207,117,907
CITADEL ADVISORS LLC removed 1,020,474 shares (-96.7%) from their portfolio in Q4 2025, for an estimated $202,788,593
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 692,708 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $137,654,933
GLENVIEW CAPITAL MANAGEMENT, LLC removed 606,326 shares (-20.7%) from their portfolio in Q3 2025, for an estimated $123,108,431
HOLOCENE ADVISORS, LP removed 584,404 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $118,657,388
PACER ADVISORS, INC. removed 538,299 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $106,970,777

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$THC Government Contracts

We have seen $270,000 of award payments to $THC over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

STERILE PROCESSING SERVICES: $135,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$THC Congressional Stock Trading

Members of Congress have traded $THC stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $THC stock by members of Congress over the last 6 months:

REPRESENTATIVE JONATHAN L. JACKSON has traded it 2 times. They made 1 purchase worth up to $50,000 on 12/10 and 1 sale worth up to $15,000 on 02/11.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$THC Analyst Ratings

Wall Street analysts have issued reports on $THC in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 01/07/2026
Barclays issued a "Overweight" rating on 11/21/2025
JP Morgan issued a "Overweight" rating on 11/13/2025
RBC Capital issued a "Outperform" rating on 10/30/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/29/2025
Guggenheim issued a "Buy" rating on 10/29/2025
UBS issued a "Buy" rating on 10/29/2025

To track analyst ratings and price targets for $THC, check out Quiver Quantitative's $THC forecast page.

$THC Price Targets

Multiple analysts have issued price targets for $THC recently. We have seen 15 analysts offer price targets for $THC in the last 6 months, with a median target of $257.0.

Here are some recent targets:

Ann Hynes from Mizuho set a target price of $265.0 on 03/12/2026
Jason Cassorla from Guggenheim set a target price of $283.0 on 03/12/2026
Whit Mayo from Leerink Partners set a target price of $264.0 on 02/20/2026
David Macdonald from Truist Securities set a target price of $270.0 on 02/17/2026
Andrew Mok from Barclays set a target price of $257.0 on 02/13/2026
Ben Hendrix from RBC Capital set a target price of $277.0 on 02/12/2026
Brian Tanquilut from Jefferies set a target price of $265.0 on 02/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.